Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
123 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H1 2017 Summary Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 24 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase JAK2 - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 2, 2, 10 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Myeloproliferative Disorders, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Atopic Dermatitis, Myelofibrosis, Asthma, Auto Inflammatory Disease, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Glioblastoma Multiforme (GBM), Leukemias, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Solid Tumor, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alopecia, Anaplastic Astrocytoma, B-Cell Leukemia, Cancer Anorexia-Cachexia Syndrome, Chronic Lymphocytic Leukemia (CLL), Dermatitis, Dermatomyositis, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Essential Thrombocythemia, Giant Cell Arteritis, Gliosarcoma, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypopharyngeal Cancer, Laryngeal Cancer, Lymphoma, Multiple Sclerosis, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Proliferative Diabetic Retinopathy (PDR), Psoriatic Arthritis, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Failure, Respiratory Tract Inflammatory Disorders, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Thalassemia, Thrombocythemia Myelofibrosis, Vitiligo and Wet (Neovascular / Exudative) Macular Degeneration. Furthermore, this report also reviewsalso reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects - The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Overview Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development Aerie Pharmaceuticals Inc Aptose Biosciences Inc AstraZeneca Plc Bristol-Myers Squibb Company Celon Pharma SA CTI BioPharma Corp Eli Lilly and Company Genentech Inc Incyte Corp Japan Tobacco Inc Nerviano Medical Sciences Srl Nippon Shinyaku Co Ltd Novartis AG Simcere Pharmaceutical Group Theravance Biopharma Inc Tragara Pharmaceuticals Inc Vectura Group Plc Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Drug Profiles AR-13154 - Drug Profile Product Description Mechanism Of Action R&D Progress AZD-1480 - Drug Profile Product Description Mechanism Of Action R&D Progress baricitinib - Drug Profile Product Description Mechanism Of Action R&D Progress BVB-808 - Drug Profile Product Description Mechanism Of Action R&D Progress CHZ-868 - Drug Profile Product Description Mechanism Of Action R&D Progress CPL-407105 - Drug Profile Product Description Mechanism Of Action R&D Progress Drugs to Inhibit JAK2 for Rheumatoid Arthritis - Drug Profile Product Description Mechanism Of Action R&D Progress JTE-052 - Drug Profile Product Description Mechanism Of Action R&D Progress MA-2014 - Drug Profile Product Description Mechanism Of Action R&D Progress NMSP-113 - Drug Profile Product Description Mechanism Of Action R&D Progress NMSP-953 - Drug Profile Product Description Mechanism Of Action R&D Progress NS-018 - Drug Profile Product Description Mechanism Of Action R&D Progress pacritinib - Drug Profile Product Description Mechanism Of Action R&D Progress ruxolitinib phosphate - Drug Profile Product Description Mechanism Of Action R&D Progress SAR-317461 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit JAK2 for Leukemia - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit JAK2 and JAK3 for Oncology and Auto Immune Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit JAK2 for Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress TD-1473 - Drug Profile Product Description Mechanism Of Action R&D Progress TD-3504 - Drug Profile Product Description Mechanism Of Action R&D Progress TG-02 - Drug Profile Product Description Mechanism Of Action R&D Progress VR-588 - Drug Profile Product Description Mechanism Of Action R&D Progress Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Dormant Products Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Discontinued Products Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Product Development Milestones Featured News & Press Releases Apr 14, 2017: U.S. FDA Issues Complete Response Letter For Baricitinib Apr 04, 2017: Aclaris Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Baricitnib for Hair Loss Disorders Mar 24, 2017: Withdrawal of the marketing authorisation application for Enpaxiq (pacritinib) Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization Feb 15, 2017: Additional Results From Pivotal RA-BEAM Study Published In New England Journal Of Medicine Show Baricitinib-Treated Patients Demonstrated Sustained Improvement In Rheumatoid Arthritis Compared To Adalimumab And Placebo Feb 13, 2017: European Commission Approves Once-Daily Olumiant Tablets For Treatment Of Adults With Moderate-To-Severe Active Rheumatoid Arthritis Feb 13, 2017: Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization Jan 13, 2017: U.S. FDA Extends Review Period For Baricitinib, An Investigational Rheumatoid Arthritis Treatment Jan 09, 2017: CTI BioPharma Announces Progress Of Pacritinib And Strategic Objectives For 2017 Jan 05, 2017: CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib Dec 30, 2016: Incyte Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi) in Graft-versus-Host Disease Dec 16, 2016: CHMP Recommends Approval of Lillys Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA) Dec 06, 2016: PERSIST-2 Phase 3 Study Of Pacritinib Versus Best Available Therapy Shows Encouraging Clinical Activity In High-Risk Patients With Advanced Myelofibrosis In Late-Breaking Session At ASH Annual Meeting Dec 04, 2016: Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi (ruxolitinib) Nov 21, 2016: CTI BioPharma Announces data on Pacritinib at ASH Annual Meeting Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Aerie Pharmaceuticals Inc, H1 2017 Pipeline by Aptose Biosciences Inc, H1 2017 Pipeline by AstraZeneca Plc, H1 2017 Pipeline by Bristol-Myers Squibb Company, H1 2017 Pipeline by Celon Pharma SA, H1 2017 Pipeline by CTI BioPharma Corp, H1 2017 Pipeline by Eli Lilly and Company, H1 2017 Pipeline by Genentech Inc, H1 2017 Pipeline by Incyte Corp, H1 2017 Pipeline by Japan Tobacco Inc, H1 2017 Pipeline by Nerviano Medical Sciences Srl, H1 2017 Pipeline by Nippon Shinyaku Co Ltd, H1 2017 Pipeline by Novartis AG, H1 2017 Pipeline by Simcere Pharmaceutical Group, H1 2017 Pipeline by Theravance Biopharma Inc, H1 2017 Pipeline by Tragara Pharmaceuticals Inc, H1 2017 Pipeline by Vectura Group Plc, H1 2017 Dormant Products, H1 2017 Dormant Products, H1 2017 (Contd..1), H1 2017 Dormant Products, H1 2017 (Contd..2), H1 2017 Dormant Products, H1 2017 (Contd..3), H1 2017 Discontinued Products, H1 2017 Discontinued Products, H1 2017 (Contd..1), H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
